The creation, approval and large-scale manufacturing of a Covid-19 vaccine in less than a year is among the most notable scientific and technological achievements in history. Led by Operation Warp Speed in the US, and with similar initiatives in other countries, including the UK, vast scientific resources have been mobilised to crack a huge global crisis. The effort has succeeded magnificently.
What governments got right
Just as significantly, by pre-ordering vaccines on a vast scale, governments guaranteed a market for any company that could produce an effective jab. The billions spent might seem like a lot of money, but it was peanuts, of course, compared to the vast cost of coping with the epidemic. It was money well spent. The interesting question, however, is this. What can any company, or indeed government, learn from the success of that project? Here are four places to start.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
1. Focus
The companies and research institutes working on creating a vaccine didn’t have to worry about diversity, market share, delivering value for different stakeholders or governance structures. In fact, they didn’t have to worry about anything other than the single overriding purpose of devising a safe and effective jab as fast as possible. Clarity of purpose makes a huge difference. We expect businesses to deliver a range of economic, social, and environmental goals, and while they might all be worthwhile, it is often more effective to have just a single objective and concentrate completely on it. It gets results.
2. Incentives matter
University research institutes have contributed hugely to the scientific work – especially Oxford and Imperial – but most of the work has been done in the private sector. Pfizer didn’t even take the money on offer from the US government because it didn’t want its scientist to be bogged down in politics and targets. Instead, patent rights have been preserved and companies are being paid standard commercial rates for the vaccines despite pressure for it all to be taken under state control. The result? Businesses have had plenty of incentives to create a vaccine, and to put in place all the infrastructure to deliver it to hundreds of millions of people because they can make money from doing so. It is very simple – but it works every time.
3. Embark on different stages of a process simultaneously
New medicines usually get created step by step. It takes a year or two to develop a drug, then another couple of years to do the trials, then a year or so for approvals, and then another year to get the factories ready and get it into the medical system. So it can be a decade before the product is on the market. If tests are done at the same time as factories are prepared, however, it can all happen much faster. From infrastructure projects to consumer goods there are lessons in that for every kind of product. Sure, it costs more, but if it makes everything happen faster, then it might be worth it.
4. Accelerate the approvals process
Finally, accelerate regulation too. Whatever the anti-vaxxers might say, there is no evidence that there have been any compromises on the safety trials for the Covid-19 vaccines. But the regulatory checks have been sped up. Instead of waiting for every test to be completed, and a huge dossier to be compiled, regulators have constantly monitored the vaccine candidates as their trials were completed. The result? They could approve drugs far more quickly. Other regulatory agencies could learn from that. Lots of industries, from finance to telecoms to the media, need supervision – but it doesn’t need to slow everything down as much as it does.
-
First Solar is set to shine – should you invest?Solar-power specialist First Solar will benefit from Donald Trump’s policies, says Matthew Partridge
-
Private assets: profit from the potential in these fundsOpinion Charlotte Cuthbertson and Tom Treanor of the Migo Opportunities Trust highlight three funds where they'd put their money
-
Camellia: an unusual tea producer that rewards patient investorsCamellia is shedding its eclectically diverse portfolio of assets to concentrate on its strengths. For investors, it's a rare opportunity
-
How to approach active ETFsActive ETFs have several advantages over other forms of open-ended investment vehicles, says David Prosser
-
Global equities that should prove resilient to the stock market’s stormsOpinion Alex Illingworth of Goshawk Asset Management highlights three diverse opportunities in global equities despite a turbulent landscape
-
US stocks are more expensive than ever after Trump's tariffsWe don’t need to second-guess the effect of Trump's tariffs to think that the rest of the world offers better value
-
How to use SAYE and SIP schemes to multiply your moneyEmployers’ savings or share-incentive plans like SAYE and SIP schemes can help top up your pension
-
Where investors can find value nowOpinion Active fund managers and blue chips on both sides of the Atlantic look appealing, says ByteTree’s Charlie Morris
-
UK equities: where to find a great British bargainUK equities are staging a comeback, but there’s still plenty of value out there, says Rupert Hargreaves
-
Just Group has the wind behind it – should you invest?Just Group, a retirement products provider, is well placed to profit from a growing annuity market
